• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

新型抗毒蕈碱药物：控制膀胱功能且口干症状较轻。

The newer antimuscarinic drugs: bladder control with less dry mouth.

作者信息

Appell Rodney A

机构信息

Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA.

出版信息

Cleve Clin J Med. 2002 Oct;69(10):761, 765-6, 768-9. doi: 10.3949/ccjm.69.10.761.

DOI:10.3949/ccjm.69.10.761
PMID:12371799
Abstract

Two newer antimuscarinic anticholinergic drugs--tolterodine and extended-release oxybutynin--are approximately as effective in treating overactive bladder as immediate-release oxybutynin, but are more tolerable. I review clinical trial data on the newer agents.

摘要

两种新型抗毒蕈碱类抗胆碱能药物——托特罗定和缓释奥昔布宁——在治疗膀胱过度活动症方面的效果与速释奥昔布宁大致相同，但耐受性更好。我回顾了关于这些新型药物的临床试验数据。

相似文献

1
The newer antimuscarinic drugs: bladder control with less dry mouth.新型抗毒蕈碱药物：控制膀胱功能且口干症状较轻。
Cleve Clin J Med. 2002 Oct;69(10):761, 765-6, 768-9. doi: 10.3949/ccjm.69.10.761.
2
Comparison of dry mouth in women treated with extended-release formulations of oxybutynin or tolterodine for overactive bladder.用奥昔布宁或托特罗定缓释制剂治疗膀胱过度活动症的女性口干情况比较。
Int Urol Nephrol. 2005;37(2):247-52. doi: 10.1007/s11255-004-4703-7.
3
Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.奥昔布宁和托特罗定缓释制剂治疗膀胱过度活动症疗效和耐受性的前瞻性、随机、双盲研究：OPERA试验结果
Mayo Clin Proc. 2003 Jun;78(6):687-95. doi: 10.4065/78.6.687.
4
Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET).每日一次的缓释托特罗定或奥昔布宁治疗膀胱过度活动症：抗毒蕈碱临床疗效试验（ACET）
Curr Med Res Opin. 2002;18(4):177-84. doi: 10.1185/030079902125000570.
5
Tolterodine: a clinical review.托特罗定：一项临床综述。
J Womens Health Gend Based Med. 2001 Oct;10(8):735-43. doi: 10.1089/15246090152636488.
6
Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.氯氮卓斯汀缓释片与酒石酸托特罗定治疗膀胱过度活动症的前瞻性随机对照试验：OBJECT研究结果
Mayo Clin Proc. 2001 Apr;76(4):358-63.
7
Comparison of tolterodine with standard treatment in pediatric patients with non-neurogenic dysfunctional voiding/over active bladder: a systematic review.托特罗定与标准治疗方案用于小儿非神经源性排尿功能障碍/膀胱过度活动症患者的比较：一项系统评价
Indian J Physiol Pharmacol. 2013 Oct-Dec;57(4):343-53.
8
Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials.每日一次服用缓释奥昔布宁治疗尿失禁的安全性和耐受性：两项4期对照临床试验的综合结果
Int Urol Nephrol. 2007;39(4):1069-77. doi: 10.1007/s11255-006-9157-7. Epub 2007 Mar 2.
9
Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients.老年与年轻患者中，每日一次托特罗定缓释制剂治疗膀胱过度活动症的疗效、安全性及耐受性
J Am Geriatr Soc. 2002 May;50(5):799-807. doi: 10.1046/j.1532-5415.2002.50203.x.
10
Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial.托特罗定缓释片与奥昔布宁速释片治疗日本和韩国膀胱过度活动症患者的临床疗效及耐受性：一项随机、安慰剂对照试验
BJU Int. 2003 Nov;92(7):741-7. doi: 10.1046/j.1464-410x.2003.04468.x.

引用本文的文献

1
Lesions in the oral cavity and esophagus caused by prescribed drugs: A review.口腔和食管的药物性损伤：综述。
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022 Mar;166(1):21-27. doi: 10.5507/bp.2021.059. Epub 2021 Nov 5.
2
Adherence to Anticholinergic Therapy and Clean Intermittent Self-Catheterization in Patients With Multiple Sclerosis.多发性硬化症患者对抗胆碱能疗法的依从性及间歇性清洁导尿
Int Neurourol J. 2018 Jun;22(2):133-141. doi: 10.5213/inj.1836054.027. Epub 2018 Jun 30.
3
Social, economic, and health utility considerations in the treatment of overactive bladder.
膀胱过度活动症治疗中的社会、经济和健康效用考量
Open Access J Urol. 2010 Feb 11;2:11-24. doi: 10.2147/rru.s4166.
4
Efficacy and tolerability of combined medication of two different antimuscarinics for treatment of adults with idiopathic overactive bladder in whom a single agent antimuscarinic therapy failed.两种不同抗毒蕈碱药物联合用药治疗单一抗毒蕈碱药物治疗失败的成人特发性膀胱过度活动症的疗效和耐受性
Can Urol Assoc J. 2013 Jan-Feb;7(1-2):E88-92. doi: 10.5489/cuaj.269.
5
Oxybutynin extended release and tolterodine immediate release : a health economic comparison.奥昔布宁缓释片和托特罗定速释片：一种健康经济学比较。
Clin Drug Investig. 2004;24(2):81-8. doi: 10.2165/00044011-200424020-00003.
6
Pharmacological management of overactive bladder : a systematic and critical review of published economic evaluations.膀胱过度活动症的药物治疗：已发表的经济学评价的系统与批判性综述
Pharmacoeconomics. 2005;23(10):995-1006. doi: 10.2165/00019053-200523100-00003.